Highmark and Sword Health expand pelvic health services with virtual physical therapy
Which clinical criteria do insurers commonly require for GLP-1 approval
When LDN Alone May Not Be Enough Some patients may experience suboptimal results with LDN alone, due to: Persistent metabolic dysregulation (like insulin resistance) Chronic inflammatory states resistant to LDNs immunomodulatory effects Co-existing conditions such as mild cognitive impairment or mood disorders Limitations with existing medications (like tramadol or other opiates) that excludes from LDN therapy, but not Microdosing GLP-1 In these cases, adding Microdosing GLP-1 may enhance outcomes by addressing metabolic and systemic inflammation more comprehensively
If youre considering semaglutide, or already taking it, youve probably done your homework on how it works
Constipation Because the GLP-1 medications decrease peristalsis, constipation is a fairly common side effect
Retatrutide In early-phase trials, Retatrutide showed substantial weight loss (up to 24.2% over 48 weeks)
